While the selective partial TAAR1 agonist Ralmitaront is currently being tested in Phase 2 clinical trials, Ulotaront (TAAR1 agonist with serotonin 5-HT1A agonist activity) has entered Phase 3 clinical studies to evaluate the treatment of adults and adolescents with schizophrenia [8,9]. The gene discussed is TAAR1; the disease is schizophrenia.